Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Dang-Nghiem Vo, Catherine Alexia, Nerea Allende-Vega, Franck Morschhauser, Roch Houot, Cedric Menard, Karin Tarte, Guillaume Cartron & Martin Villalba. (2018) NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. OncoImmunology 7:4.
Read now
Read now
Peter H Wiernik. (2013)
Lenalidomide in lymphomas and chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 14:4, pages 475-488.
Read now
Read now
Petr Szturz, Zdeněk Adam, Jana Chovancová, Olga Stehlíková, Martin Klabusay, Zdeněk Řehák, Renata Koukalová, Marta Krejčí, Luděk Pour, Lenka Zahradová, Roman Hájek & Jiří Mayer. (2012) Lenalidomide: a new treatment option for Castleman disease. Leukemia & Lymphoma 53:10, pages 2089-2091.
Read now
Read now
Ioannis A. Voutsadakis & Anne Cairoli. (2012) A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes. Leukemia & Lymphoma 53:5, pages 779-788.
Read now
Read now
Petr Szturz, Zdeněk Adam, Zdeněk Řehák, Renata Koukalová, Radka Šlaisová, Olga Stehlíková, Jana Chovancová, Martin Klabusay, Marta Krejčí, Luděk Pour, Roman Hájek & Jiří Mayer. (2012) Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncologica 51:3, pages 412-415.
Read now
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Read now
Articles from other publishers (77)
Chaitrali Shevkar & Abhijeet S. Kate. 2023. Natural Immunomodulators: Promising Therapy for Disease Management. Natural Immunomodulators: Promising Therapy for Disease Management
216
242
.
Katherine O. Kopp, Margaret E. Greer, Elliot J. Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson & Nigel H. Greig. (2023) A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules 13:5, pages 747.
Crossref
Crossref
Ahmed Ismail Eatmann, Esraa Hamouda, Heba Hamouda, Hossam Khaled Farouk, Afnan W. M. Jobran, Abdallah A. Omar, Alyaa Khaled Madeeh, Nada Mostafa Al-dardery, Salma Elnoamany, Eman Gamal Abd-Elnasser, Abdullah Muhammed Koraiem, Alhassan Ali Ahmed, Mohamed Abouzid & Marta Karaźniewicz-Łada. (2023) Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. Metabolites 13:4, pages 543.
Crossref
Crossref
Pugazhenthan Thangaraju, Sree Sudha Tanguturi Yella, Siva Sanker Reddy Lingareddygari & Kota Sesha Brahma Shree Krishna Sasanka. (2022) Repurposing Thalidomide, its Analogue and Apremilast for Possible
Antiviral in Situation of Severe COVID Cytokine Syndrome. Infectious Disorders - Drug Targets 22:8.
Crossref
Crossref
Jiří Minařík & Sabina Ševčíková. (2022) Immunomodulatory Agents for Multiple Myeloma. Cancers 14:23, pages 5759.
Crossref
Crossref
Junichi Yamamoto, Tomoko Asatsuma‐Okumura, Takumi Ito, Yuki Yamaguchi & Hiroshi Handa. 2022. Protein Homeostasis in Drug Discovery. Protein Homeostasis in Drug Discovery
283
315
.
Ran Tao, Xiaorong Peng, Xiang Liu, Lijun Xu, Junwei Su, Guanjing Lang, Ying Huang & Biao Zhu. (2022) Outcome of Lenalidomide Treatment for Cognitive Impairment Caused by Immune Reconstitution Inflammatory Syndrome in Patients with HIV-Related Cryptococcal Meningitis. Journal of Inflammation Research Volume 15, pages 5327-5336.
Crossref
Crossref
Devesh Rai, Raseen Tariq, Muhammad Waqas Tahir, Medhat Chowdhury, Abdul Wahab, Adnan Kharsa, Dhrubajyoti Bandyopadhyay, Scott C. Feitell, Vishal Parikh, Wilbert S. Aronow, Gregg M. Lanier, Elliot Levine, Gregg C. Fonarow & Vivek Kaul. (2021) Primary and Secondary Prevention Strategies for Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device: A Systematic Review and Network Meta-analysis. Current Problems in Cardiology 46:11, pages 100835.
Crossref
Crossref
Lakshmikirupa Sundaresan, Suvendu Giri, Himanshi Singh & Suvro Chatterjee. (2021) Repurposing of thalidomide and its derivatives for the treatment of SARS‐coV‐2 infections: Hints on molecular action. British Journal of Clinical Pharmacology 87:10, pages 3835-3850.
Crossref
Crossref
Michael A. Firer, Michael Y. Shapira & Galia Luboshits. (2021) The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. Cancers 13:16, pages 4090.
Crossref
Crossref
Elaheh Asgari Dafe, Nastaran Rahimi, Nina Javadian, Pegah Dejban, Monika Komeili, Sepideh Modabberi, Mehdi Ghasemi & Ahmad Reza Dehpour. (2021) Effect of Lenalidomide on Pentylenetetrazole-Induced Clonic Seizure Threshold in Mice: A Role for N-Methyl-D-Aspartic Acid Receptor/Nitric Oxide Pathway. Journal of Epilepsy Research 11:1, pages 6-13.
Crossref
Crossref
Magdalena M. Brune, Georg Stüssi, Pontus Lundberg, Visar Vela, Dominik Heim, Markus G. Manz, Eugenia Haralambieva, Thomas Pabst, Yara Banz, Mario Bargetzi, Rainer Grobholz, Martin Fehr, Sergio Cogliatti, Gert J. Ossenkoppele, Bob Löwenberg, Christina Biaggi Rudolf, Qiyu Li, Jakob Passweg, Luca Mazzuchelli, Michael Medinger & Alexandar Tzankov. (2021) Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Annals of Hematology 100:5, pages 1169-1179.
Crossref
Crossref
Naoto Ujiie, Yoshitaka Enomoto, Naruhito Takido, Yasushi Kawaharada, Masashi Zuguchi & Yosuke Kubota. (2021) Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report. International Journal of Surgery Case Reports 81, pages 105834.
Crossref
Crossref
Eun Jee Kim, Joon Ye Kim, Hoon Young Choi, Hyojung Lee, Juhan Lee, Myoung Soo Kim, Yu Seun Kim, Kyu Ha Huh & Beom Seok Kim. (2021) Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells. Yonsei Medical Journal 62:2, pages 137.
Crossref
Crossref
Yoo Jin Jung, David Tweedie, Michael T. Scerba & Nigel H. Greig. (2019) Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Frontiers in Cell and Developmental Biology 7.
Crossref
Crossref
Alexander M. Lesokhin, Susan Bal & Ashraf Z. Badros. (2019) Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer Immunology Research 7:8, pages 1224-1229.
Crossref
Crossref
Reza Baradaran Eftekhari, Niloufar Maghsoudnia, Shabnam Samimi, Ali Zamzami & Farid Abedin Dorkoosh. (2019) Co-Delivery Nanosystems for Cancer Treatment: A Review. Pharmaceutical Nanotechnology 7:2, pages 90-112.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Nobuo Takemori, Goro Imai, Kazuo Hoshino, Akishi Ooi & Masaru Kojima. (2018) A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report. Journal of Medical Case Reports 12:1.
Crossref
Crossref
Hartel Paul. (2018) Lenalidomide as potential treatment in small cell neuroendocrine lung cancer with del 5q. Scientific Journal of Genetics and Gene Therapy, pages 002-003.
Crossref
Crossref
Wolfgang Knauf, Ali Aldaoud, Christoph Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach & Karin Potthoff. (2018) Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials. Leukemia Research 68, pages 90-97.
Crossref
Crossref
Eun Jee Kim, Jae Geun Lee, Joon Ye Kim, Seung Hwan Song, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Beom Seok Kim & Yu Seun Kim. (2017) Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. Immunology 152:4, pages 628-637.
Crossref
Crossref
Emanuella de Castro, Thamile Luciane Reus, Alessandra Melo de Aguiar, Andrea Rodrigues Ávila & Tatiana de Arruda Campos Brasil de Souza. (2017) Procaspase-activating compound-1 induces apoptosis in Trypanosoma cruzi. Apoptosis 22:12, pages 1564-1577.
Crossref
Crossref
Khan Rana Sami Ullah, Yu-Lin Xiong, Ying-Lei Miao, Saeed Ummair & Wei Dai. (2017) Thalidomide and thalidomide analogues in treatment of patients with inflammatory bowel disease: Meta-analysis. World Journal of Meta-Analysis 5:5, pages 124-131.
Crossref
Crossref
Belen Lopez-Millan, Rafael Diaz de la Guardia, Heleia Roca-Ho, Carmen M García-Herrero, Jessie R Lavoie, Michael Rosu-Myles, Elena Gonzalez-Rey, Francisco O'Valle, Gabriel Criado, Mario Delgado & Pablo Menendez. (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Experimental & Molecular Medicine 49:2, pages e290-e290.
Crossref
Crossref
Bishoy El-Aarag, Tomonari Kasai, Junko Masuda, Hussein Agwa, Magdy Zahran & Masaharu Seno. (2017) Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2. Biomedicine & Pharmacotherapy 85, pages 549-555.
Crossref
Crossref
Erez Eitan, Emmette R. Hutchison, Nigel H. Greig, David Tweedie, Hasan Celik, Soumita Ghosh, Kenneth W. Fishbein, Richard G. Spencer, Carl Y. Sasaki, Paritosh Ghosh, Soumen Das, Susheela Chigurapati, James Raymick, Sumit Sarkar, Srinivasulu Chigurupati, Sudipta Seal & Mark P. Mattson. (2015) Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Experimental Neurology 273, pages 151-160.
Crossref
Crossref
Ling-Feng Dong, Jin Yao, Xiao-Qun Wang, Kun Shan, Hong Yang, Biao Yan & Qin Jiang. (2015) Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder. Biochemical and Biophysical Research Communications 465:4, pages 678-684.
Crossref
Crossref
Feten Béji, Sonia Taktouk, Jihène Ben Kraïem, Salem S. Al-Deyab & Hassen Amri. (2015) Two-Step Synthesis of Multifunctional γ-Lactams from γ-Lactone. Journal of Heterocyclic Chemistry 52:5, pages 1576-1579.
Crossref
Crossref
Courtney D DiNardo, Naval Daver, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Marina Konopleva, Naveen Pemmaraju, Hui Yang, Sherry Pierce, William Wierda, Carlos Bueso-Ramos, Keyur P Patel, Jorge E Cortes, Farhad Ravandi, Hagop M Kantarjian & Guillermo Garcia-Manero. (2015) Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. The Lancet Haematology 2:1, pages e12-e20.
Crossref
Crossref
Lohith S Bachegowda & Stefan K Barta. (2014) Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncology 10:15, pages 2509-2528.
Crossref
Crossref
Daniel L. Suzman, Sosipatros A. Boikos & Michael A. Carducci. (2014) Bone-targeting agents in prostate cancer. Cancer and Metastasis Reviews 33:2-3, pages 619-628.
Crossref
Crossref
Roba Talaat, Waheba El-Sayed, Hussein Agwa, Amira Gamal-Eldeen, Shaden Moawia & Magdy Zahran. (2014) Novel thalidomide analogs: Anti-angiogenic and apoptotic effects on Hep-G2 and MCF-7 cancer cell lines. Biomedicine & Aging Pathology 4:3, pages 179-189.
Crossref
Crossref
Madhav Desai, Kate Newberry, Zhishuo Ou, Michael Wang & Liang Zhang. (2014) Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Therapeutic Advances in Hematology 5:3, pages 91-101.
Crossref
Crossref
Nobuo Takemori, Toshio Fukuda & Masaru Kojima. (2014) Follow-Up Study of a Multiple Myeloma Patient Successfully Treated with Clarithromycin (CAM), Low-Dose Lenalidomide and Low-Dose Dexamethasone: Significance and Possible Mechanism of Action of CAM as an Add-On Therapy. Case Reports in Clinical Medicine 03:12, pages 674-684.
Crossref
Crossref
Ola Landgren. (2013) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology 2013:1, pages 478-487.
Crossref
Crossref
Madhav Desai, Kate J Newberry, Jorge Romaguera, Liang Zhang, Zhishuo Ou & Michael Wang. (2013) Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Meletios A. Dimopoulos, Evangelos Terpos & Ruben Niesvizky. (2013) How lenalidomide is changing the treatment of patients with multiple myeloma. Critical Reviews in Oncology/Hematology 88, pages S23-S35.
Crossref
Crossref
Noopur Raje & Sundar JagannathLoredana SantoNoopur Raje. 2013. Current & Emerging Therapeutics for Multiple Myeloma. Current & Emerging Therapeutics for Multiple Myeloma
42
66
.
Jiri Minarik, Viera Sandecka, Vladimir Maisnar, Evzen Gregora, Ivan Spicka, David Starostka, Hana Plonkova, Jiri Jarkovsky, Lenka Walterova, Marek Wrobel, Dagmar Adamova, Tomas Pika, Hana Melicharova, Ludek Pour, Jakub Radocha, Petr Pavlicek, Jan Straub, Jaromir Gumulec, Jaroslav Bacovsky, Zdenek Adam, Vlastimil Scudla & Roman Hajek. (2013) 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. Leukemia Research 37:9, pages 1063-1069.
Crossref
Crossref
Miao Xu, Yu Hou, Lei Sheng & Jun Peng. (2013) Therapeutic effects of thalidomide in hematologic disorders: a review. Frontiers of Medicine 7:3, pages 290-300.
Crossref
Crossref
T Scullen, L Santo, S Vallet, M Fulciniti, H Eda, D Cirstea, K Patel, N Nemani, A Yee, A Mahindra & N Raje. (2013) Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia 27:8, pages 1715-1721.
Crossref
Crossref
Daniel Heintel, Alberto Rocci, Heinz Ludwig, Arnold Bolomsky, Simona Caltagirone, Martin Schreder, Sabine Pfeifer, Heinz Gisslinger, Niklas Zojer, Ulrich Jäger & Antonio Palumbo. (2013)
High expression of cereblon (
CRBN
) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
. British Journal of Haematology 161:5, pages 695-700.
Crossref
Crossref
Hessel H. van der Zee, Jon D. Laman, Jurr Boer & Errol P. Prens. (2012) Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Experimental Dermatology 21:10, pages 735-739.
Crossref
Crossref
Ke-Jia Xu, Jiangning Song & Xing-Ming Zhao. (2012) The drug cocktail network. BMC Systems Biology 6:S1.
Crossref
Crossref
Stephanie Coates, Alan Barker & Stephen Spurgeon. (2011) Reversible pulmonary toxicity due to lenalidomide. Journal of Oncology Pharmacy Practice 18:2, pages 284-286.
Crossref
Crossref
Y. Loriot, C. Massard & K. Fizazi. (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Annals of Oncology 23:5, pages 1085-1094.
Crossref
Crossref
Adrian AlegreIsabel VicuñaBeatriz Aguado. (2011) Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Clinical Medicine Insights: Oncology 6, pages CMO.S7275.
Crossref
Crossref
Roberta Zappasodi & Massimo Di Nicola. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
115
157
.
Antonia Lopez-Girona, Daniel Heintel, Ling-Hua Zhang, Derek Mendy, Svetlana Gaidarova, Helen Brady, Justin Blake Bartlett, Peter H. Schafer, Martin Schreder, Arnold Bolomsky, Bernadette Hilgarth, Niklas Zojer, Heinz Gisslinger, Heinz Ludwig, Tom Daniel, Ulrich Jäger & Rajesh Chopra. (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. British Journal of Haematology 154:3, pages 325-336.
Crossref
Crossref
Chad C. Bjorklund, Wencai Ma, Zhi-Qiang Wang, R. Eric Davis, Deborah J. Kuhn, Steven M. Kornblau, Michael Wang, Jatin J. Shah & Robert Z. Orlowski. (2011) Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. Journal of Biological Chemistry 286:13, pages 11009-11020.
Crossref
Crossref
T. Guglielmelli, S. Bringhen, S. Rrodhe, F. Gay, F. Cavallo, A. Berruti, V. Montefusco, E. Piro, G. Benevolo, M.T. Petrucci, T. Caravita, M. Offidani, P. Corradini, M. Boccadoro, G. Saglio & A. Palumbo. (2011) Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European Journal of Cancer 47:6, pages 814-818.
Crossref
Crossref
Rajesh Rajpal, Paul Dowling, Justine Meiller, Colin Clarke, William G. Murphy, Robert O'Connor, Malcolm Kell, Constantine Mitsiades, Paul Richardson, Kenneth C. Anderson, Martin Clynes & Peter O'Gorman. (2011) A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. PROTEOMICS 11:8, pages 1391-1402.
Crossref
Crossref
A Scuto, P Krejci, L Popplewell, J Wu, Y Wang, M Kujawski, C Kowolik, H Xin, L Chen, Y Wang, L Kretzner, H Yu, W R Wilcox, Y Yen, S Forman & R Jove. (2010) The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25:3, pages 538-550.
Crossref
Crossref
Craig B. Reeder & Stephen M. Ansell. (2011) Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 117:5, pages 1453-1462.
Crossref
Crossref
Katherine E. WarrenStewart GoldmanIan F. PollackJason FangusaroPaula SchaiquevichClinton F. StewartDana WallaceSusan M. BlaneyRoger PackerTobey MacDonaldRegina JakackiJames M. BoyettLarry E. Kun. (2011) Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018. Journal of Clinical Oncology 29:3, pages 324-329.
Crossref
Crossref
Ola Landgren & S. Vincent Rajkumar. (2011) Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology 48:1, pages 66-72.
Crossref
Crossref
Zhijian Xiao, Zefeng Xu, Yue Zhang, Tiejun Qin, Hongli Zhang & Liwei Fang. (2011) Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study. Leukemia Research 35:1, pages 61-65.
Crossref
Crossref
Battuvshin Badamtseren, Erdenezaya Odkhuu, Naoki Koide, Abedul Haque, Yoshikazu Naiki, Shoji Hashimoto, Takayuki Komatsu, Tomoaki Yoshida & Takashi Yokochi. (2011) Thalidomide inhibits interferon-γ-mediated nitric oxide production in mouse vascular endothelial cells. Cellular Immunology 270:1, pages 19-24.
Crossref
Crossref
Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss & Ola Landgren. (2010) Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma Myeloma and Leukemia 10:4, pages 248-257.
Crossref
Crossref
Nianhang Chen, Henry Lau, Somesh Choudhury, Xiaomin Wang, Mahmoud Assaf & Oscar L. Laskin. (2013) Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses. The Journal of Clinical Pharmacology 50:7, pages 767-774.
Crossref
Crossref
Thomas Reske, Mariateresa Fulciniti & Nikhil C. Munshi. (2010) Mechanism of action of immunomodulatory agents in multiple myeloma. Medical Oncology 27:S1, pages 7-13.
Crossref
Crossref
Sagar Lonial. (2009) Future directions in immunomodulatory therapy. Medical Oncology 27:S1, pages 62-66.
Crossref
Crossref
Charles Gullo, Liang Kai Koh, Wan Lu Pang, Kian Tong Ho, Shi Hao Tan & Herbert Schwarz. (2010) Inhibition of Proliferation and Induction of Apoptosis in Multiple Myeloma Cell Lines by CD137 Ligand Signaling. PLoS ONE 5:5, pages e10845.
Crossref
Crossref
Wai M. Liu, Holger Laux, Jake Y. Henry, Thomas B. Bolton, Angus G. Dalgleish & Christine Galustian. (2009) A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Molecular Biology Reports 37:4, pages 1801-1814.
Crossref
Crossref
R. García‐Sanz, T.J. González‐López, L. Vázquez, G. Hermida, I.F. Graciani & J.F. San Miguel. (2010) The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma. European Journal of Haematology 84:3, pages 266-270.
Crossref
Crossref
Richard J. Lin, James J. Curran, Todd M. Zimmerman, Jie Song, Timothy B. Niewold & Nadera J. Sweiss. (2010) Lenalidomide for the Treatment of Cryoglobulinemia and Undifferentiated Spondyloarthropathy in a Patient With Multiple Myeloma. JCR: Journal of Clinical Rheumatology 16:2, pages 90-91.
Crossref
Crossref
Dolly G. Aguilera, Tadanori Tomita, Veena Rajaram, Jason Fangusaro, Ben Z. Katz, Stanford Shulman & Stewart Goldman. (2009) Glioblastoma Multiforme in a Patient With Chronic Granulomatous Disease Treated With Subtotal Resection, Radiation, and Thalidomide. Journal of Pediatric Hematology/Oncology 31:12, pages 965-969.
Crossref
Crossref
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning & Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, pages 6-22.
Crossref
Crossref
Jaume Capdevila, Jose Perez-Garcia, Gabriel Obiols & Josep Tabernero. (2009) Targeted therapies in thyroid cancer. Targeted Oncology 4:4, pages 275-285.
Crossref
Crossref
Sheeba K. Thomas, Tiffany A. Richards & Donna M. Weber. (2009) Novel Agents for Relapsed and/or Refractory Multiple Myeloma. The Cancer Journal 15:6, pages 485-493.
Crossref
Crossref
Enrico Balleari & Andrea Bruzzone. (2009) Unusual myeloma relapse after thalidomide therapy: The dark side of the moon?. Leukemia Research 33:9, pages 1164-1165.
Crossref
Crossref
Kazuyuki Shimizu & Junji Itoh. (2009) A possible link between Trousseau's syndrome and tissue factor producing plasma cells. American Journal of Hematology 84:6, pages 382-385.
Crossref
Crossref
Peter H. Wiernik. (2008) Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology 10:1-2, pages 1-15.
Crossref
Crossref
Sabine Tricot, Céline Berthon, Marie-Dominique Venon, Julie Gay, Remy Dulery, Aldo M RoccaroTeru HideshimaIrene M GhobrialThierry Facon & Xavier Leleu. (2009) Thalidomide in multiple myeloma in the elderly. Aging Health 5:1, pages 7-18.
Crossref
Crossref
Ayman A Saad, Manish Sharma & Gerald M Higa. (2009) Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era. Annals of Pharmacotherapy 43:2, pages 329-338.
Crossref
Crossref
A. Keith Stewart. (2009) Novel therapies for relapsed myeloma. Hematology 2009:1, pages 578-586.
Crossref
Crossref